gone refocu market maintain buy
maintain buy rate pt share
follow result saw revenu pre-announce top
origin btig/consensu estim despit weaker
aesthet perform fulli divest gyn surgic molecular continu
perform well driven strong sale execut increas panther adopt
via increas assay ep in-lin btig/consensu follow
cynosur divestitur organ growth guidanc increas
guidanc non-gaap ep increas larg driven asr
plan remov cynosur off-set somewhat increas invest
core busi net item non-gaap ep guidanc would flat
slightli share like see pressur result dynam
think long-term improv core busi growth rate key
area gyn surgic diagnost encourag breast health remain
steadi share trade ntm ep leverag ratio room tuck-in
acquisit healthi product pipelin stabl q/q dynam within breast
result servic revenu continu share repurchas continu
recommend share month basi
refocus cynosur divestitur management note organ growth
guidanc rais primarili due fundament remain core
busi feel divestitur cynosur abl provid someth
tailwind organ growth particular management call abil
ou organ directli focu core busi indirectli
bolt-on achiev lower leverag greater
remov cynosur key driver increas organ revenu growth
management note core busi strength necessarili remov weaker
 tabl follow divestitur account asr
end leverag ratio within rang
management state comfort management enthusiast pursu
smaller division-l strategi consist bolt-on acquisit
comment busi would receiv focu management cite
driver seat ou perform across strong
post y/i organ growth result strongest diagnost gyn
surgic dd growth seen segment abl continu
bolster breast health come
valuat rate buy pt base month
adj ep estim risk discuss
idc btig estim compani document
million except per share amount
believ improv busi overal expect manag abl turnaround aesthet
leadership chang believ take sever quarter sens shift investor sentiment away
aesthet emphasi core busi believ combin reason valuat stabl
busi exclus aesthet opportun upsid management grow aesthet busi keep us
buy look month longer term view intern growth d/new product launch
margin expans consist capit alloc reason
assum consolid superson imag result
blood screen revenu run
base case assum revenu adj ep in-lin
guidanc call revenu rang
adj ep rang
make sell product
gyn surgic skelet health
product selenia
diagnost assay panther
system thinprep
upsid current base case would assum area breast health
diagnost gyn surgic grow faster assum think
like opportun higher expect growth within gyn
surgic busi molecular diagnost breast health continu
remain steadi separ would expect expand margin
expect newer high margin product ad portfolio
downsid would come increas competit gyn surgic slower
growth area cytolog breast health
report result total revenu y/i in-lin previous pre-announc
result report constant currenc revenu growth y/i organ growth revenu
geographi broke us europ asia-pacif rest world
segment report breast health revenu y/i beat btig consensu estim call
y/i y/i respect breast imag intervent breast solut revenu
came y/i y/i compar btig estim call y/i
diagnost revenu came y/i beat btig consensu estim call y/i
y/i respect revenu ex-blood came y/i within diagnost cytolog
perinat molecular diagnost revenu came y/i y/i compar btig
estim call y/i y/i respect
gyn surgic skelet health revenu came y/i y/i compar btig
consensu estim call y/i y/i
revenu divest aesthet busi came
 adj gross margin bp estim sg percentag revenu
came compar estim respect overal adj ep came
in-lin btig consensu estim
made follow chang model
make sever chang model first remov aesthet revenu forecast go
forward introduc revenu estim model well increas expect ssi
due time off-set modest growth area breast run result today quarter
diagnost gyn surgic line see slight increas revenu result
 introduc estim model within beyond divest aesthet
portion busi function in-lin previou disclosur increas gm estim
reduc sg percent revenu within year move ebit margin higher forecast
offset tweak interest expens tax modestli beyond lower project
share count result asr
actualsbtig estimate variancebreast sale sale cytolog perinat molecular diagnost blood screen surgic sale novasur myosur sale sale revenu market admin incom incom gross bp sg spend bp spend bp ebit bp tax bpssourc btig estim compani filingsvari
rate buy pt base month adjust ep estim multipl
comp group reflect compani slightli lower revenu growth risk rate price target includ
adopt chang reimburs diagnost price novasur competit chang regul impact
revenu incom btig estim compani filingsnewold chang
holog incom million except etot sell gener oper interest incom incom tax incom share net calendar loss oper btig estim compani report
holog revenu million except growthbreast y/i growthbreast btig research estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
